Introduction
============

Lung cancer is the leading cause of cancer mortality amongst males globally, and has surpassed breast cancer as the leading cause of cancer mortality amongst females in developed countries ([@b1-ol-0-0-8167]). The 5-year survival rate has remained poor, at \~17%, over previous decades despite multiple novel aggressive therapies ([@b2-ol-0-0-8167]). Furthermore, the majority of patients are diagnosed whilst in the advanced stages of the disease, due to a lack of clinical presentation within the early stages. Thus, novel targets and approaches are required to improve the treatment and diagnosis of lung cancer.

Recently, the human microbiome has been an active area of research. A previous study demonstrated that the human intestine contains \~100 trillion microorganisms, including \~500-1,000 different species ([@b3-ol-0-0-8167]). Although the gastrointestinal tract is the major colony site for these microorganisms, other sites of colonization include the oral cavity, the respiratory tract, the urogenital tract and the skin. At present, these complex microbiomes remain incompletely characterized. However, many studies have focused on the association between the microbiome and cancer, including *Helicobacter pylori* and gastric carcinoma ([@b4-ol-0-0-8167]), Epstein-Barr virus and nasopharyngeal carcinoma ([@b5-ol-0-0-8167]), and Human papillomavirus and cervical cancer ([@b6-ol-0-0-8167]). The majority of the earlier studies focus on a single pathogenic bacteria or virus.

Developments in metagenomics including 16S rRNA gene pyrosequencing techniques and bioinformatics ([@b7-ol-0-0-8167]) have assisted in providing an understanding of the role of the human microbiome within cancer. In the oral cavity, changes in the level of microorganisms are considered to be associated with the development of oral cancer ([@b8-ol-0-0-8167]). In the pancreatic cancer, the levels of *Neisseria elongata* and *Streptococcus mitis* in the saliva have been revealed to be increased in patients with pancreatic cancer, and may become the microbial biomarkers for pancreatic cancer ([@b9-ol-0-0-8167]). In the colon, certain bacterial biofilms were associated with colorectal cancer, and fecal microbiota may be a potential target for early-stage detection methods for colorectal cancer ([@b10-ol-0-0-8167],[@b11-ol-0-0-8167]). In the respiratory tract, microbiota is associated with many lung diseases, including chronic obstructive pulmonary disease (COPD) ([@b12-ol-0-0-8167],[@b13-ol-0-0-8167]), asthma ([@b14-ol-0-0-8167]) and lung cancer ([@b15-ol-0-0-8167]). These studies demonstrated that the human microbiome is associated with cancer.

Numerous studies have indicated that inflammation is an important factor in the promotion of carcinogenesis in pulmonary adenocarcinoma ([@b16-ol-0-0-8167],[@b17-ol-0-0-8167]). Additionally, recent studies revealed that the microbiome serves an important role in the regulation of inflammation through numerous mechanisms, such as influencing the metabolism of short-chain fatty acids, which were recognized to be beneficial to the host. Furthermore, the level of inflammation of the host may be reduced when imbalances within the microbiome are reversed ([@b18-ol-0-0-8167],[@b19-ol-0-0-8167]). A previous epidemiological study demonstrated that \~16% of types of human cancer worldwide were associated with infectious agents or infection-associated chronic inflammation, with a higher percentage in developing countries, at 22.9%, compared with developed countries, at 7.4% ([@b20-ol-0-0-8167]).

Understanding the role of the microbiome in lung cancer is important to identify novel targets and approaches for the treatment and diagnosis of the disease. In the present study, a urethane-induced pulmonary adenocarcinoma model was used to explore the roles of the microbiomes in the lower respiratory and intestinal tracts, and of inflammation, determined by measuring the levels of inflammatory cytokines nuclear factor κB (NF-κB), tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and IL-6 present in lung adenocarcinoma. Additionally, prebiotics were used to alter the microbiome and levels of inflammation in urethane-induced pulmonary adenocarcinoma. The result revealed that inflammation and the microbiome may serve an important role in the carcinogenesis of lung cancer, and that prebiotics may assist the function of treatments of lung cancer by modulating the microbiome and the inflammatory response.

Materials and methods
=====================

### Animals, groups and sample collection

A total of 15 6-week-old male BALB/c mice, weighing 18--22 g, were sourced from Vital River Laboratories Co., Ltd., (Beijing, China), and were randomly distributed into 3 groups with access to tap water and an unrestricted diet. Each group included 5 animals in 1 cage. The environment was maintained at 19--22°C, with 40--60% humidity and a standard 12 h day/night rhythm. The animals were given 2 weeks to adapt to the novel environment.

All experiments (performed once) included: A control group (C); a urethane-induced adenocarcinoma group (U) and a prebiotics-gavage intervention group (P). The cases of pulmonary adenocarcinoma were induced by intraperitoneal (i.p.) injection of 1 g/kg dose of urethane in 100 µl saline once per week for 8 weeks. The control group was injected i.p. with 100 µl saline, as described previously ([@b21-ol-0-0-8167],[@b22-ol-0-0-8167]). Group P was treated intragastrically with 15 mg/kg prebiotics 5 times/week continuously for 16 weeks, beginning at the 5th week subsequent to the first injection of the urethane, whilst groups C and U were treated with equivalent saline. The prebiotics in this experiment were: Dietary fiber (extracted from endive and konjak), *Cordyceps*, Ginseng, *Ganoderma lucidum*, Seaweed, *Hericium* and *Lycium barbarum* polysaccharides.

All of the mice were sacrificed (via exsanguination following anesthesia with 5% isoflurane) at the end of the 20th week after the first injection of urethane. Fresh stool and sera samples were collected and stored at −80°C prior to sacrifice. The bronchoalveolar lavage (BAL) procedure was performed, as described in previous studies ([@b22-ol-0-0-8167],[@b23-ol-0-0-8167]). All BAL samples were stored at −80°C, and the lung tissue was fixed in 10% paraformaldehyde for histopathological analyses.

### Serum inflammation measurements

NF-κB, TNF-α, IL-1β and IL-6 levels in serum were detected through a mouse (NF-κB, TNF-α, IL-1β and IL-6) ELISA kit (Elabscience Biotechnology Co., Ltd., Wuhan, China). The optical density was read at 450 nm using a microtiter plate reader.

### DNA extraction

Extraction of the DNA from 180--220 mg of the fresh stool samples using the TIANamp Stool DNA kit (DP328; TIANGEN Biotech Co., Ltd., Beijing, China) was carried out according to protocol of the manufacturer. However, 400 g of the BAL samples were first thawed and centrifuged for 5 min at room temperature and 400 × g, and the supernatant was collected. The supernatant samples were then centrifuged at 13,210 × g for 5 min at room temperature again. Subsequently, the bacterial DNA from the BAL samples was extracted using the TIANamp Micro DNA kit (DP316; TIANGEN Biotech Co., Ltd.) according to protocol outlined previously ([@b23-ol-0-0-8167]). All DNA quality was assessed using gel electrophoresis and spectrophotometry, and was stored at −80°C prior to use.

### 16S sequencing and bioinformatics

16S rRNA (V4) sequencing was carried out to analyze the changes in the microbiome in accordance with protocol described in a previous study ([@b24-ol-0-0-8167]). The sequences were quality-checked and clustered into *de novo* operational taxonomic units (OTUs) at the 97% similarity threshold for the production of OTUs using UPARSE software (25, <http://drive5.com/uparse/>). The most abundant sequence in each OTU was chosen as the representative sequence. UCHIME software was used to remove chimeric sequences ([@b26-ol-0-0-8167]). Outliers with a low sequence count and microbial diversity were removed. Mothur software (version 1.35.1; <https://www.mothur.org/>) was then used to calculate indices of Shannon diversity and richness ([@b27-ol-0-0-8167]). The Ribosomal Database Project (RDP) Classifier software (version 16; <https://rdp.cme.msu.edu/>) was used to classify sequences.

### Statistical analysis

The data was analyzed using a 2-sample t-test and SPSS 14.0 software (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference. Two sample t-tests were performed to identify significant differences between families and OTUs between each group, and data are presented as the mean ± standard deviation.

Results
=======

### Constructing and identifying the model of lung cancer

As demonstrated in [Fig. 1](#f1-ol-0-0-8167){ref-type="fig"}, at the end of the 20th week, subsequent to the first injection of urethane, each mouse in groups U and P displayed altered histopathology and the development of lung adenocarcinoma tumors, whilst the control group did not.

### Prebiotics inhibited urethane-induced elevation of the level of inflammation (NF-κB, TNF-α, IL-1β, IL-6) in serum

The levels of the inflammatory markers NF-κB, TNF-α, IL-1β and IL-6 were markedly higher in groups U and P than in the control group after urethane-induced treatment, as illustrated in [Fig. 2](#f2-ol-0-0-8167){ref-type="fig"}. When the urethane-induced adenocarcinoma mice were treated with prebiotics, the levels of these inflammatory markers markedly decreased to similar levels observed within the control.

### Richness and diversity of microbiome in lung and intestine of mice

To investigate the change in the composition of the microbiome, the bacterial richness and Shannon diversity indices of each group were calculated and compared for the lung tissues, with samples obtained from BAL, and for the intestinal tissues, with samples obtained from feces. The results are demonstrated in [Fig. 3A-D](#f3-ol-0-0-8167){ref-type="fig"}.

In the lower airways, the mean richness values were 570.6±194.2, 594.2±250.4, 583.4±160.0 for groups C, U and P, respectively, and were not statistically significant as illustrated in ([Fig. 3A](#f3-ol-0-0-8167){ref-type="fig"}) (U vs. C; P=0.8719; P vs. C, P=0.9122; P vs. U, P=0.9372). In the intestinal tract, the mean richness values which were 515.4±51.8, 510.4±81.8, 512.4±41.3 for groups C, U and P, respectively, and were also not significantly different, as demonstrated in [Fig. 3B](#f3-ol-0-0-8167){ref-type="fig"} (U vs. C; P=0.9109; P vs. C, P=0.9218; P vs. U, P=0.9623). In the aforementioned 3 groups, differences in the Shannon diversity indices were not statistically significant in the lower respiratory or the intestinal tracts, as demonstrated in [Fig. 3C](#f3-ol-0-0-8167){ref-type="fig"} (U vs. C; P=0.9978; P vs. C, P=0.7978; P vs. U; P=0.8837) and [Fig. 3D](#f3-ol-0-0-8167){ref-type="fig"} (U vs. C; P=0.4056; P vs. C, P=0.5106; P vs. U, P=0.6586).

### Composition of microbial communities at the class level

A total of 30 classes of bacteria were identified using the RDP classifier. Gammaproteobacteria, Chloroplasts, Alphaproteobacteria, Bacteroidia, Bacilli, Clostridia and Betaproteobacteria were the most abundant classes in BAL, and occupied 94.9% of the microbiota in the 3 BC, BU and BP groups, as illustrated in [Fig. 4](#f4-ol-0-0-8167){ref-type="fig"}. No significant difference was observed in the types of classes of bacteria between the groups C, P and U in the lower respiratory tract microbiome. In the intestinal tract, Clostridia and Bacteroidia were the most abundant types of class, and occupied 88.99% of the microbiota in the 3 (FC, FU and FP) groups. No significant variation in the types of classes of bacteria was observed between the 3 groups in these samples.

### Composition of microbial communities at the family level

To analyze the systematic differences in microbial communities among groups C, U and P, 68 families except the 'Others' group, comprising other types of microbes whose total ratio was \<0.5%, were clustered based on their respective relative abundance, as demonstrated in [Fig. 5](#f5-ol-0-0-8167){ref-type="fig"}. In the lower respiratory tract microbiome, no significant difference was identified between groups C, U and P. In the intestinal tract, the levels of abundance of the Oxalobacteraceae and Paenibacillaceae families were lower in group U compared with group C. The levels of abundance of these families were higher in group P compared with group U, although the difference was not statistically significant. The levels of abundance of the Enterobacteriaceae, Moraxellaceae, and Shewanellaceae families significantly increased in group P compared with group U. Additionally, all abundance levels of these families were lower in group U compared with group C, although the difference was not statistically significant (the data that exhibited significant variation is listed in [Table I](#tI-ol-0-0-8167){ref-type="table"}, and others are not shown).

### Effect of prebiotics to the OTU of microbiome

Finally, the OTU was used to analyse the difference between microbiota. In the lower respiratory tract, the levels of abundance of Clostridiales, Lachnospiraceae, Pedobacter and iii1-15 families decreased in group U compared with group C, and the abundance of the Clostridiales and Lachnosipraceae families became equivalent to the level in the control group in group P when the prebiotics were administered. The levels of abundance of S24-7 and Erythroba families increased in group U compared with group C, and the level in group P became equivalent to the levels of the control group when prebiotics were administered. These data are demonstrated in [Table II](#tII-ol-0-0-8167){ref-type="table"}; other families without significant differences among groups were not included due to the large number within this group. In the intestinal tract, significant differences between the microbiomes of each group were observed, as illustrated in [Table III](#tIII-ol-0-0-8167){ref-type="table"}. For example, the level of abundance of the S24-7, Bacteroidales and Firmicutes families increased in group U compared with group C, becoming equivalent to those in the control group subsequent to the administration of prebiotics, as demonstrated in group P. The abundance levels of Clostridiales, Ruminococcus and Flexispira families exhibited a decrease in group U compared with group C, becoming equivalent to those in the control group subsequent to the administration of prebiotics, as demonstrated in group P. Furthermore, the Lachnospiraceae family demonstrated a similar result within the lower respiratory tract, as summarized in [Table III](#tIII-ol-0-0-8167){ref-type="table"}. Other families without significant differences between the groups were not included, due to the large number within this group.

Discussion
==========

At present, intestinal microbiota are considered to be the most important type of microbiome in humans, with known associations with numerous diseases including obesity ([@b28-ol-0-0-8167]), diabetes ([@b29-ol-0-0-8167]), inflammatory bowel disease ([@b30-ol-0-0-8167]) and cancer ([@b9-ol-0-0-8167],[@b18-ol-0-0-8167]). In experimental animals and humans, there is evidence to support the hypothesis that the commensal microbiome serves an important role in carcinogenesis, tumor progression and therapy ([@b18-ol-0-0-8167]).

The association between the intestinal microbiome, inflammation and cancer has also been widely studied. For example, a recent study concluded that the intestinal microbiome affected the intestine of the host and other organs such as the lungs, due to the circulation of metabolites produced in the intestines throughout the body ([@b31-ol-0-0-8167]). Multiple studies have demonstrated that the microbiome existing in the respiratory tract is associated with numerous diseases of the lungs, including COPD ([@b12-ol-0-0-8167],[@b13-ol-0-0-8167]), asthma ([@b14-ol-0-0-8167]) and lung cancer ([@b15-ol-0-0-8167]). Additionally, the microbiome of the respiratory tract serves an important role in the exacerbation of chronic lung diseases ([@b32-ol-0-0-8167]). Otherwise, the microbiomes of the airway and intestinal tracts may affect each other through the gut-lung axle ([@b23-ol-0-0-8167],[@b33-ol-0-0-8167]). For example, a study conducted by Madan *et al* ([@b34-ol-0-0-8167]) indicated that changes in diet resulted in an alteration of the intestinal tract microflora, and in an alteration in the respiratory tract microflora. Previous studies have demonstrated that respiratory and intestinal microbiomes are associated with inflammation, which was demonstrated to be one of the most important factors in the carcinogenesis of lung cancer ([@b16-ol-0-0-8167],[@b17-ol-0-0-8167]). Investigation into the association between microbiomes in the lower airways and the intestinal tract, inflammation and lung cancer is therefore required.

Furthermore, the development of metagenomics, including 16S rRNA gene pyrosequencing technique and bioinformatics ([@b7-ol-0-0-8167]) have provided an increased understanding of the role of the human microbiome in the development of cancer. The microbiome has become an important area of research. However, data associating the changes in the airway and intestinal microbiome to lung cancer remain scarce. Thus, the aim of the present study was to investigate and explain the association between microbiota, inflammation and lung cancer through a urethane-induced pulmonary adenocarcinoma mouse model, which is widely used in research in lung cancer ([@b21-ol-0-0-8167]) and the microbiome ([@b35-ol-0-0-8167]).

The present study identified no significant variation in the richness and diversity of microbiome among the 3 groups, as demonstrated in [Fig. 1](#f1-ol-0-0-8167){ref-type="fig"}, which may be associated with the individual variation and the sample number of each group. However, there were some significant variations between the intestinal and the respiratory tract microbiomes at a familial level, which is demonstrated in [Tables I](#tI-ol-0-0-8167){ref-type="table"}, [II](#tII-ol-0-0-8167){ref-type="table"} and [III](#tIII-ol-0-0-8167){ref-type="table"}. The levels of abundance of the S24-7, Bacteroidales and Firmicutes families were increased in the intestinal tract of urethane-induced pulmonary adenocarcinoma mice (U) compared with the control group (C), but were reduced when prebiotics were administered to the urethane-induced pulmonary adenocarcinoma mice (group P). The abundance levels of the Clostridiales family were decreased in the intestinal tract of urethane-induced pulmonary adenocarcinoma mice (U) compared with the control group (C), but were increased when prebiotics were administered to the urethane-induced pulmonary adenocarcinoma mice (group P). Additionally, the S24-7, Clostridiales and Lachnospiraceae families exhibited similar variation in the respiratory and intestinal tracts, and the variation between each group and different organ sites- the lungs and the intestine-indicated that an interaction existed between the intestinal and respiratory tract microbiomes, and prebiotics may affect these microbiomes, which was similar to data revealed in a previous study ([@b34-ol-0-0-8167]).

Multiple previous studies identified similar changes in the levels of abundance of the Clostridiales, Bacteroidales and S24-7 families observed in the present study. For example, Baxter *et al* ([@b36-ol-0-0-8167]) demonstrated that the number of Bacteroidales families present was associated with a higher rate of tumorigenesis, whilst the numbers of Clostridiales families present was associated with a lower rate of tumorigenesis. In the present study, the levels of abundance of the Bacteroidales and S24-7 families increased in group U compared with group C in the lower respiratory and intestinal tracts, whilst the level of abundance of the Clostridiales families decreased. These variations were also found in a study by Schwab *et al* ([@b37-ol-0-0-8167]) concerning murine microbiota activity and interactions with the host during acute inflammation and recovery. Furthermore, a reduction in the level of abundance of intestinal Clostridiales families was reported to precede the development of nosocomial *Clostridium difficile* infection ([@b38-ol-0-0-8167]), and decreased abundance in Clostridiales families was strongly correlated with inflammatory bowel disease (IBD) status ([@b39-ol-0-0-8167]). Whilst an increase in the relative proportion of Bacteroidales families was identified in high-fat-fed mice with high levels of inflammation ([@b40-ol-0-0-8167]), Bacteroidales families were also found in oral mucosae, and exhibited higher levels of abundance in recurrent aphthous stomatitis patients compared with healthy controls ([@b41-ol-0-0-8167]). Thus, the variations in Clostridials, Bacteroidales and S24-7 families in the lower respiratory and intestinal tracts may exert significant effects on the levels of inflammation and the carcinogenesis of lung cancer.

In the present study, the results from the analysis of the inflammatory markers revealed that the inflammation level in the urethane-induced pulmonary adenocarcinoma mice was higher than the level of the control group, which was similar to the data observed in previous studies ([@b21-ol-0-0-8167],[@b42-ol-0-0-8167]). Additionally, the level of inflammation decreased when prebiotics were administered to the group of pulmonary adenocarcinoma mice. The prebiotics used consisted of a mixture plant polysaccharides, which are utilized by the microbiome to promote the growth of certain microorganisms, particularly probiotic microorganisms such as Lactobacillus, the level of which increased in group P in the intestinal tract, as demonstrated in [Table III](#tIII-ol-0-0-8167){ref-type="table"}.

In conclusion, the carcinogen urethane affected the levels of inflammation and the composition of the microbiome, and prebiotics inhibited the urethane-induced elevation of the level of inflammation in mice, possibly through the regulation of the microbiome in the intestinal and respiratory tracts, but did not inhibit the development of pulmonary adenocarcinoma that was possibly associated with the interference time and the concentration of the prebiotics. Additional studies are required to investigate these issues. In the present study, it was demonstrated that prebiotics may increase levels of inflammation and the composition of the microbiome in the intestinal and respiratory tracts, and improve the treatment of lung cancer. Understanding the role of the intestinal and respiratory microbiomes is important, in order to identify novel targets and approaches for improving the treatment and diagnosis of lung cancer.
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![Differences in pathology between each group. The right column is hematoxylin and eosin staining (d=5 µm) results from each group, and the left column is the lung tissue from each group. Arrows denote lesions on the lung surface. At the end of the 20th week, subsequent to the first injection of urethane, each mouse in groups U and P exhibited altered histopathology and the development of lung adenocarcinoma tumors, whilst the control group did not. C, control group; U, urethane-induced adenocarcinoma group; P, prebiotics-gavage intervention group.](ol-15-05-6352-g00){#f1-ol-0-0-8167}

![Levels of inflammation (pg/ml) in sera in each group (n=5 for each group). The levels of inflammatory markers (A) IL-1β, (B) TNF-α, (C) IL-6 and (D) NF-κB were significantly higher in both groups U (P\<0.0001, \<0.0001, \<0.0001 and \<0.0001 respectively) and P (P\<0.0001, \<0.0002, \<0.0001 and 0.0002 respectively) than in the control group C. The level of inflammatory markers was significantly decreased in group P compared with group U (P\<0.0001, \<0.0001, \<0.0001 and \<0.0001 respectively). Data are presented as the mean ± standard deviation. \*P\<0.05 vs. group C. ^\#^P\<0.05 vs. group U. IL-1β, Interleukin-1β; TNF-α, tumor necrosis factor α; NF-κB, nuclear factor κB; C, control group; U, urethane-induced adenocarcinoma group; P, prebiotics-gavage intervention group.](ol-15-05-6352-g01){#f2-ol-0-0-8167}

![Boxplot demonstrating indices of the (A and B) richness and (C and D) Shannon diversity of the intestinal and respiratory microbiota. No significant differences in the richness or diversity were observed among the 3 groups. BAL, bronchoalveolar lavage; BC, microbiota from BAL in control group C; BU, microbiota from BAL in urethane-induced adenocarcinoma group U; BP, microbiota from BAL in prebiotics-gavage intervention group P; FC, microbiota from fecal matter in control group C; FU, microbiota from fecal matter in urethane-induced adenocarcinoma group U; FP, microbiota from fecal matter in prebiotics-gavage intervention group P.](ol-15-05-6352-g02){#f3-ol-0-0-8167}

![Microbial community comparisons and relative abundances at the class level. BAL, bronchoalveolar lavage, BC, microbiota from BAL in control group C; BU, microbiota from BAL in urethane-induced adenocarcinoma group U; BP, microbiota from BAL in prebiotics-gavage intervention group P; FC, microbiota from fecal matter in control group C; FU, microbiota from fecal matter in urethane-induced adenocarcinoma group U; FP, microbiota from fecal matter in prebiotics-gavage intervention group P. Each bar graph demonstrates the mean abundance of 5 mice in each group.](ol-15-05-6352-g03){#f4-ol-0-0-8167}

![Microbial community comparisons and relative abundances at the Family level. BAL, bronchoalveolar lavage, BC, microbiota from BAL in control group C; BU, microbiota from BAL in urethane-induced adenocarcinoma group U; BP, microbiota from BAL in prebiotics-gavage intervention group P; FC, microbiota from fecal matter in control group C; FU, microbiota from fecal matter in urethane-induced adenocarcinoma group U; FP, microbiota from fecal matter in prebiotics-gavage intervention group P.](ol-15-05-6352-g04){#f5-ol-0-0-8167}

###### 

Relative abundances of bacterial families in the lower respiratory and intestinal tracts.

                       Relative mean abundance (%)                                                             
  -------------------- ----------------------------- --------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Enterobacteriaceae   9.375 (BC)                    13.042 (BU)                                               2.084 (BP)^[c](#tfn3-ol-0-0-8167){ref-type="table-fn"}^
  Sphingomonadaceae    0.564 (BC)                    0.551 (BU)                                                1.059 (BP)^[a](#tfn1-ol-0-0-8167){ref-type="table-fn"},[c](#tfn3-ol-0-0-8167){ref-type="table-fn"}^
  Oxalobacteraceae     0.006 (FC)                    0.000 (FU)^[a](#tfn1-ol-0-0-8167){ref-type="table-fn"}^   0.006 (FP)
  Paenibacillaceae     0.002 (FC)                    0.000 (FU)^[b](#tfn2-ol-0-0-8167){ref-type="table-fn"}^   0.005 (FP)
  Enterobacteriaceae   0.074 (FC)                    0.016 (FU)                                                0.048 (FP)^[c](#tfn3-ol-0-0-8167){ref-type="table-fn"}^
  Moraxellaceae        0.188 (FC)                    0.001 (FU)                                                0.052 (FP)^[c](#tfn3-ol-0-0-8167){ref-type="table-fn"}^
  Shewanellaceae       0.038 (FC)                    0.001 (FU)                                                0.006 (FP)^[c](#tfn3-ol-0-0-8167){ref-type="table-fn"}^

P\<0.05

P\<0.01 vs. group C

P\<0.05, vs. group U. BC, microbiota from BAL in control group C; BU, microbiota from BAL in urethane-induced adenocarcinoma group U; BP, microbiota from BAL in prebiotics-gavage intervention group P; FC, microbiota from fecal matter in control group C; FU, microbiota from fecal matter in urethane-induced adenocarcinoma group U; FP, microbiota from fecal matter in prebiotics-gavage intervention group P.

###### 

OTU of the respiratory microbiome.

                    Average of relative abundance in different group                                                      
  ----------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  Clostridiales     2.8                                                0.8^[a](#tfn4-ol-0-0-8167){ref-type="table-fn"}^   1.2
  Lachnospiraceae   2.6                                                0.0^[b](#tfn5-ol-0-0-8167){ref-type="table-fn"}^   0.8
  Pedobacter        2.4                                                0.2^[b](#tfn5-ol-0-0-8167){ref-type="table-fn"}^   0.0^[b](#tfn5-ol-0-0-8167){ref-type="table-fn"}^
  iii1-15           1.2                                                0.0^[b](#tfn5-ol-0-0-8167){ref-type="table-fn"}^   0.0^[b](#tfn5-ol-0-0-8167){ref-type="table-fn"}^
  Rikenellaceae     0.0                                                7.0^[b](#tfn5-ol-0-0-8167){ref-type="table-fn"}^   1.0
  S24-7             0.2                                                4.2^[b](#tfn5-ol-0-0-8167){ref-type="table-fn"}^   2.4
  Erythroba         0.4                                                2.2                                                0^[c](#tfn6-ol-0-0-8167){ref-type="table-fn"}^

P\<0.05

P\<0.001 vs. group BC

P\<0.001 vs. group BU. BC, microbiota from BAL in control group C; BU, microbiota from BAL in urethane-induced adenocarcinoma group U; BP, microbiota from BAL in prebiotics-gavage intervention group P; OTU, operational taxonomic units.

###### 

OTU of the intestinal microbiome.

                            Average of relative abundance in different group                                                            
  ------------------------- -------------------------------------------------- -------------------------------------------------------- -----------------------------------------------------
  S24-7                     1,187.5                                              4,050.6^[a](#tfn7-ol-0-0-8167){ref-type="table-fn"}^   863.2^[d](#tfn10-ol-0-0-8167){ref-type="table-fn"}^
  Clostridiales               41.8                                               10.4^[a](#tfn7-ol-0-0-8167){ref-type="table-fn"}^      57.0^[d](#tfn10-ol-0-0-8167){ref-type="table-fn"}^
  Bacteroidales               0.0                                                0.6^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       0.0^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  Firmicutes                  1.0                                                7.2^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       0.0^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  Ruminococcus                85                                                 27.4^[a](#tfn7-ol-0-0-8167){ref-type="table-fn"}^      40.6
  Ruminococcus *gn*           24.4                                               5^[b](#tfn8-ol-0-0-8167){ref-type="table-fn"}^         17.2
  Bacteroides                 0.2                                                1.8^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       0.8
  Flexispira                  132.6                                              0.0^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       84.0
  Adlercreutzia               0.0                                                1.6^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       0.6
  Oxalobacteraceae            1.2                                                0.0^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       1.8
  Lachnospiraceae             18.4                                               2.2^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       10.6
  Desulfovibrionaceae         35                                                 0.2^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       0.0^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^
  Paenibacillus               0.8                                                0.0^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^       2.0
  AF12                        0.4                                                141.4^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^     48.0^[c](#tfn9-ol-0-0-8167){ref-type="table-fn"}^
  Bacteria                    0                                                  0                                                      2.0^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  Lactobacillus               0.4                                                0                                                      3.2^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  *Lactobacillus ruminis*     0.2                                                0                                                      0.6^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  *Lactococcus garvieae*      1.8                                                2.8                                                    0.0^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  Rikenellaceae               0                                                  0                                                      1.4^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  *Shewanella algae*          15.4                                               0.4                                                    2.4^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  Ruminococcaceae             1.2                                                2.2                                                    0.4^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^
  *Escherichia coli*        2,850.4                                            4,058.6                                                  510.0^[d](#tfn10-ol-0-0-8167){ref-type="table-fn"}^
  Helicobacteraceae           0.8                                                0.2                                                    3.6^[e](#tfn11-ol-0-0-8167){ref-type="table-fn"}^

P\<0.05

P\<0.01

P\<0.001 vs. group FC

P\<0.05

P\<0.001 vs. group FU. FC, microbiota from feces in the control group C; FU, microbiota from feces in the urethane-induced adenocarcinoma group U; FP, microbiota from feces in the prebiotics-gavage intervention group P.
